|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Schering-Plough
Acceleron Pharma
|
|
gptkbp:advertising
|
gptkb:Mr._Thomas_A._Cech
gptkb:Dr._David_W._Johnson
gptkb:Mr._David_A._Williams
gptkb:Mr._Kenneth_C._Frazier
gptkb:Dr._Julie_Gerberding
Mr. Michael J. McGowan
Mr. John A. McGowan
Mr._Caroline_L._Dyer
|
|
gptkbp:CEO
|
gptkb:Robert_M._Davis
gptkb:Mr._Kenneth_C._Frazier
gptkb:Mr._David_W._Johnson
gptkb:Mr._Robert_M._Davis
Mr._Caroline_L._Dyer
|
|
gptkbp:clinicalTrials
|
Phase 3 trials
Phase 1 trials
Phase 2 trials
|
|
gptkbp:community
|
gptkb:Mr._David_A._Williams
|
|
gptkbp:customerService
|
gptkb:Mr._Thomas_A._Cech
|
|
gptkbp:developer
|
gptkb:Dr._Julie_L._Gerberding
|
|
gptkbp:employees
|
approximately 74,000
|
|
gptkbp:founded
|
1891
|
|
gptkbp:founder
|
gptkb:George_Merck
|
|
gptkbp:globalPresence
|
gptkb:Mr._Thomas_A._Cech
gptkb:Mr._David_A._Williams
|
|
gptkbp:headquarters
|
gptkb:Kenilworth,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck & Co.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:internationalCooperation
|
Mr._Caroline_L._Dyer
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:IAVI
|
|
gptkbp:philanthropy
|
gptkb:Merck_Foundation
|
|
gptkbp:productionLocation
|
Mr. John A. McGowan
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
diabetes medications
|
|
gptkbp:receives_funding_from
|
Mr._Caroline_L._Dyer
|
|
gptkbp:regulatoryCompliance
|
gptkb:Dr._Julie_L._Gerberding
Mr. John A. McGowan
|
|
gptkbp:research
|
gptkb:Dr._Roger_Perlmutter
|
|
gptkbp:research_focus
|
diabetes
cancer
vaccines
cardiovascular diseases
infectious diseases
|
|
gptkbp:revenue
|
$48.7 billion (2020)
|
|
gptkbp:social_responsibility
|
gptkb:Mr._Kenneth_C._Frazier
|
|
gptkbp:stockExchange
|
MRK
|
|
gptkbp:subsidiary
|
gptkb:Merck_Sharp_&_Dohme
|
|
gptkbp:supplyChain
|
gptkb:Mr._David_A._Williams
gptkb:Mr._David_W._Johnson
|
|
gptkbp:tactics
|
gptkb:Mr._Robert_M._Davis
|
|
gptkbp:website
|
www.merck.com
|